Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Connell W. PRO: Endoscopic surveillance minimizes the risk of cancer. Am J Gastroenterol 2004;99(9):1631-3
   PubMed Web of Science ®Google Scholar
• Ramos M, Llagostera M, Esteva M, et al. Knowledge and attitudes of primary healthcare patients regarding population-based screening for colorectal cancer. BMC Cancer 2011;11(1):408
   PubMed Web of Science ®Google Scholar
• Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91(5):434-7
   PubMed Web of Science ®Google Scholar
• Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 2005;100(6):1393-403
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436-44
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Bonavita E, Barajon I, et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013;218(11):1402-10
   PubMed Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013;33(Suppl 1):S79-84
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Pages F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011;30(1):5-12
   PubMed Web of Science ®Google Scholar
• Fridman WH, Dieu-Nosjean MC, Pages F, et al. The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron 2013;6(2):117-22
   PubMedGoogle Scholar
• Restifo NP. A “big data” view of the tumor “immunome”. Immunity 2013;39(4):631-2
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39(4):782-95
   PubMed Web of Science ®Google Scholar
• Galon J, Pages F, Marincola FM, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012;10:205
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4
   PubMed Web of Science ®Google Scholar
• Di Caro G, Marchesi F, Laghi L, Grizzi F. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 2013;17(9):1088-95
   PubMed Web of Science ®Google Scholar
• Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27(35):5944-51
   PubMed Web of Science ®Google Scholar
• Laghi L, Bianchi P, Miranda E, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009;10(9):877-84
   PubMed Web of Science ®Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14(6):e218-28
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353(25):2654-66
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sozzani S, et al. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004;14(3):155-60
   PubMed Web of Science ®Google Scholar
• Allavena P, Sica A, Solinas G, et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008;66(1):1-9
   PubMed Web of Science ®Google Scholar
• Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992;13(7):265-70
   PubMedGoogle Scholar
• Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008;222:155-61
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23(11):549-55
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009;27:451-83
   PubMed Web of Science ®Google Scholar
• Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012;122(3):787-95
   PubMed Web of Science ®Google Scholar
• Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010;184(9):4810-18
   PubMed Web of Science ®Google Scholar
• Roca H, Varsos ZS, Sud S, et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009;284(49):34342-54
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25(12):677-86
   PubMed Web of Science ®Google Scholar
• Mills CD, Kincaid K, Alt JM, et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164(12):6166-73
   PubMed Web of Science ®Google Scholar
• Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117(5):1155-66
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11(10):889-96
   PubMed Web of Science ®Google Scholar
• Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006;177(10):7303-11
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009;9(10):692-703
   PubMed Web of Science ®Google Scholar
• Mantovani A, Biswas SK, Galdiero MR, et al. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013;229(2):176-85
   PubMed Web of Science ®Google Scholar
• Lin JY, Li XY, Tadashi N, Dong P. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chin J Cancer 2011;30(4):280-6
   PubMedGoogle Scholar
• Wei Q, Fang W, Ye L, et al. Density of tumor associated macrophage correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Vasiljeva O, Papazoglou A, Kruger A, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006;66(10):5242-50
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16(2):91-102
   PubMed Web of Science ®Google Scholar
• Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9(4):239-52
   PubMed Web of Science ®Google Scholar
• Schoppmann SF, Horvat R, Birner P. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol Rep 2002;9(3):455-60
   PubMed Web of Science ®Google Scholar
• Hotchkiss KA, Ashton AW, Klein RS, et al. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003;63(2):527-33
   PubMed Web of Science ®Google Scholar
• Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8(8):618-31
   PubMed Web of Science ®Google Scholar
• Granata F, Frattini A, Loffredo S, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol 2010;184(9):5232-41
   PubMed Web of Science ®Google Scholar
• Schmidt T, Carmeliet P. Blood-vessel formation: bridges that guide and unite. Nature 2010;465(7299):697-9
   PubMed Web of Science ®Google Scholar
• Mantovani A. The growing diversity and spectrum of action of myeloid-derived suppressor cells. Eur J Immunol 2010;40(12):3317-20
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012;7(12):e50946
   PubMed Web of Science ®Google Scholar
• Erreni M, Mantovani A, Allavena P. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron 2011;4(2):141-54
   PubMedGoogle Scholar
• Forssell J, Oberg A, Henriksson ML, et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007;13(5):1472-9
   PubMed Web of Science ®Google Scholar
• Edin S, Wikberg ML, Oldenborg PA, Palmqvist R. Macrophages: good guys in colorectal cancer. Oncoimmunology 2013;2(2):e23038
   PubMed Web of Science ®Google Scholar
• Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011;11(8):519-31
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009;16(3):183-94
   PubMed Web of Science ®Google Scholar
• Gungor N, Knaapen AM, Munnia A, et al. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis 2010;25(2):149-54
   PubMed Web of Science ®Google Scholar
• Sandhu JK, Privora HF, Wenckebach G, Birnboim HC. Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model. Am J Pathol 2000;156(2):509-18
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9(5):361-71
   PubMed Web of Science ®Google Scholar
• Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994;305(2):253-64
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7):1073-81
   PubMed Web of Science ®Google Scholar
• Granot Z, Henke E, Comen EA, et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011;20(3):300-14
   PubMed Web of Science ®Google Scholar
• Scapini P, Morini M, Tecchio C, et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 2004;172(8):5034-40
   PubMed Web of Science ®Google Scholar
• Chavakis T, Cines DB, Rhee JS, et al. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J 2004;18(11):1306-8
   PubMed Web of Science ®Google Scholar
• Scapini P, Nesi L, Morini M, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002;168(11):5798-804
   PubMed Web of Science ®Google Scholar
• Ai S, Cheng XW, Inoue A, et al. Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. Biochem Biophys Res Commun 2007;364(2):395-401
   PubMed Web of Science ®Google Scholar
• Queen MM, Ryan RE, Holzer RG, et al. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005;65(19):8896-904
   PubMed Web of Science ®Google Scholar
• Wislez M, Rabbe N, Marchal J, et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 2003;63(6):1405-12
   PubMed Web of Science ®Google Scholar
• Imai Y, Kubota Y, Yamamoto S, et al. Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol 2005;20(2):287-93
   PubMed Web of Science ®Google Scholar
• Tecchio C, Scapini P, Pizzolo G, Cassatella MA. On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol 2013;23(3):159-70
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Ludwig AT, Earel JK, et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005;106(10):3474-82
   PubMed Web of Science ®Google Scholar
• Tanaka H, Ito T, Kyo T, Kimura A. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol 2007;78(5):389-98
   PubMed Web of Science ®Google Scholar
• Hofman PM. Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. World J Gastroenterol 2010;16(46):5790-800
   PubMed Web of Science ®Google Scholar
• Albrethsen J, Moller CH, Olsen J, et al. Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur J Cancer 2006;42(17):3057-64
   PubMed Web of Science ®Google Scholar
• Lee HJ, Lee EK, Lee KJ, et al. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 2006;118(10):2490-7
   PubMed Web of Science ®Google Scholar
• Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010;16(2):219-23
   PubMed Web of Science ®Google Scholar
• Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013;23(3):200-7
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999;189(4):487-95
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study. BMC Cancer 2001;1:7
   PubMed Web of Science ®Google Scholar
• Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41(17):2645-54
   PubMed Web of Science ®Google Scholar
• Baeten CI, Castermans K, Hillen HF, Griffioen AW. Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol 2006;4(11):1351-7
   PubMed Web of Science ®Google Scholar
• Rao HL, Chen JW, Li M, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS One 2012;7(1):e30806
   PubMed Web of Science ®Google Scholar
• Akishima-Fukasawa Y, Ishikawa Y, Akasaka Y, et al. Histopathological predictors of regional lymph node metastasis at the invasive front in early colorectal cancer. Histopathology 2011;59(3):470-81
   PubMed Web of Science ®Google Scholar
• Droeser RA, Hirt C, Eppenberger-Castori S, et al. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS ONE 2013;8(5):e64814
   PubMed Web of Science ®Google Scholar
• Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010;21(1):27-39
   PubMed Web of Science ®Google Scholar
• Pan J, Burdick MD, Belperio JA, et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 2006;176(3):1456-64
   PubMed Web of Science ®Google Scholar
• Musha H, Ohtani H, Mizoi T, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005;116(6):949-56
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010;138(4):1429-40
   PubMed Web of Science ®Google Scholar
• Ohtani H, Jin Z, Takegawa S, et al. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 2009;217(1):21-31
   PubMed Web of Science ®Google Scholar
• Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009;69(7):3077-85
   PubMed Web of Science ®Google Scholar
• Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005;26(1):41-7
   PubMed Web of Science ®Google Scholar
• Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007;67(10):4725-31
   PubMed Web of Science ®Google Scholar
• Fridman WH, Mlecnik B, Bindea G, et al. Immunosurveillance in human non-viral cancers. Curr Opin Immunol 2011;23(2):272-8
   PubMed Web of Science ®Google Scholar
• Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69(5):2000-9
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
   PubMed Web of Science ®Google Scholar
• Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177(10):7398-405
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Kono K, Kawaguchi Y, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008;122(10):2286-93
   PubMed Web of Science ®Google Scholar
• Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 2012;22(4):327-34
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295-307
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol 2013;3:107
   PubMedGoogle Scholar
• Roncarolo MG, Gregori S, Lucarelli B, et al. Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev 2011;241(1):145-63
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12(4):298-306
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27(2):186-92
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Lanzavecchia A, et al. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 2012;119(19):4430-40
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13(15 Pt 1):4345-54
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Puentes F, Borsellino G, et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005;105(7):2877-86
   PubMed Web of Science ®Google Scholar
• Menning A, Hopken UE, Siegmund K, et al. Distinctive role of CCR7 in migration and functional activity of naive – and effector/memory-like Treg subsets. Eur J Immunol 2007;37(6):1575-83
   PubMed Web of Science ®Google Scholar
• Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010;185(9):4977-82
   PubMed Web of Science ®Google Scholar
• Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1(6):475-82
   PubMed Web of Science ®Google Scholar
• Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 2010;10(4):236-47
   PubMed Web of Science ®Google Scholar
• Mauri C, Ehrenstein MR. The ‘short’ history of regulatory B cells. Trends Immunol 2008;29(1):34-40
   PubMed Web of Science ®Google Scholar
• Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008;224:201-14
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro – versus anti-tumor immunity. Cancer Metastasis Rev 2010;29(2):309-16
   PubMed Web of Science ®Google Scholar
• Di Caro G, Bergomas F, Grizzi F, et al. Occurrence of tertiary lymphoid tissue is associated to T cell infiltration and predicts better prognosis in early stage colorectal cancers. Clin Cancer Res 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012;38(5):451-66
   PubMed Web of Science ®Google Scholar
• Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8(12):711-19
   PubMed Web of Science ®Google Scholar
• McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90(2):215-19
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448-54
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013;39(5):534-40
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Branchini C, Guallar E, et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008;123(5):1133-40
   PubMed Web of Science ®Google Scholar
• Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010;172(4):407-18
   PubMed Web of Science ®Google Scholar
• Prizment AE, Anderson KE, Visvanathan K, Folsom AR. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2011;20(2):297-307
   PubMed Web of Science ®Google Scholar
• Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27(13):2217-24
   PubMed Web of Science ®Google Scholar
• Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20(1):15-26
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG, Zacho J, et al. C-reactive protein and the risk of cancer: a Mendelian randomization study. J Natl Cancer Inst 2010;102(3):202-6
   PubMedGoogle Scholar
• Toriola AT, Cheng TY, Neuhouser ML, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 2013;132(11):2648-58
   PubMed Web of Science ®Google Scholar
• Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008;68(1):323-8
   PubMed Web of Science ®Google Scholar
• Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011;140(3):799-808. quiz e711
   PubMed Web of Science ®Google Scholar
• Song M, Wu K, Ogino S, et al. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 2013;108(9):1891-8
   PubMed Web of Science ®Google Scholar
• Joshu CE, Tsilidis KK, Peskoe SB, et al. The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes Control 2014;25(4):409-18
   PubMed Web of Science ®Google Scholar
• Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88(1):218-30
   PubMed Web of Science ®Google Scholar
• Mallappa S, Sinha A, Gupta S, Chadwick SJ. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis 2013;15(3):323-8
   PubMed Web of Science ®Google Scholar
• Ding PR, An X, Zhang RX, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010;25(12):1427-33
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008;34(1):55-60
   PubMed Web of Science ®Google Scholar
• Carruthers R, Tho LM, Brown J, et al. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis 2012;14(10):e701-7
   PubMed Web of Science ®Google Scholar
• Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009;16(3):614-22
   PubMed Web of Science ®Google Scholar
• Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003;83(4):222-6
   PubMed Web of Science ®Google Scholar
• Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int J Colorectal Dis 2010;25(2):135-40
   PubMed Web of Science ®Google Scholar
• Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000;7(2):133-8
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Ahn-Luong L, Garnero P, et al. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003;88(1):255-9
   PubMed Web of Science ®Google Scholar
• Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011;9:18
   PubMed Web of Science ®Google Scholar
• Ramsey S, Lamb GW, Aitchison M, McMillan DC. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 2006;95(8):1076-80
   PubMed Web of Science ®Google Scholar
• Takenawa J, Kaneko Y, Fukumoto M, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991;83(22):1668-72
   PubMedGoogle Scholar
• He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013;155(2):384-96
   PubMed Web of Science ®Google Scholar
• Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994;29(4):423-9
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999;85(12):2526-31
   PubMed Web of Science ®Google Scholar
• Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 2013;39(1):89-96
   PubMed Web of Science ®Google Scholar
• Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005;11(11):1639-43
   PubMed Web of Science ®Google Scholar
• Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor. Tumour Biol 2005;26(4):186-94
   PubMedGoogle Scholar
• Sasaki Y, Takeda H, Sato T, et al. Serum Interleukin-6, insulin, and HOMA-IR in male individuals with colorectal adenoma. Clin Cancer Res 2012;18(2):392-9
   PubMed Web of Science ®Google Scholar
• Kantola T, Klintrup K, Vayrynen JP, et al. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 2012;107(10):1729-36
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the anti-tumor activity of Trabectedin. Cancer Cell 2013;23:249-62
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010;362(10):875-85
   PubMed Web of Science ®Google Scholar
• Zhou Q, Peng RQ, Wu XJ, et al. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 2010;8:13
   PubMed Web of Science ®Google Scholar
• Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS ONE 2012;7(10):e47045
   PubMed Web of Science ®Google Scholar
• Saltzman BS, Yamamoto JF, Decker R, et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res 2008;68(4):1236-44
   PubMed Web of Science ®Google Scholar
• Berghella AM, Pellegrini P, Del Beato T, et al. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 1998;45(5):241-9
   PubMed Web of Science ®Google Scholar
• Shibata M, Takekawa M. Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer. Oncology 1999;56(1):54-8
   PubMed Web of Science ®Google Scholar
• Kawamura M, Toiyama Y, Tanaka K, et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer 2012;48(14):2244-51
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Fujikawa H, Kawamura M, et al. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J oncol 2012;40(2):560-566
   PubMed Web of Science ®Google Scholar
• Matsushita K, Toiyama Y, Tanaka K, et al. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol 2012;19(Suppl 3):S518-27
   PubMed Web of Science ®Google Scholar
• Fitzgerald SP, McConnell RI, Huxley A. Simultaneous analysis of circulating human cytokines using a high-sensitivity cytokine biochip array. J Proteome Res 2008;7(1):450-5
   PubMed Web of Science ®Google Scholar
• Bunger S, Haug U, Kelly FM, et al. Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen 2011;16(9):1018-26
   PubMedGoogle Scholar